Peptide Regulatory Status and FAERS Safety Signals

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Clinical Question

What is the current regulatory status of commonly used peptides, and what safety signals have emerged from clinical trial data and post-marketing surveillance?

Evidence Snapshot

• Regulatory Designations: Numerous peptides (BPC-157, TB-500, CJC-1295, etc.) are currently designated as Category 2 bulk substances, indicating significant safety risks or lack of safety data for routine compounding.
• Warning Letters: Several providers, including Tailor Made Compounding and Predator Nutrition, have received FDA warning letters regarding peptide distribution.
• FAERS Data: Over 187,757 GLP-1 RA reports have been logged in the FAERS database through 2023, with strong signals for gastrointestinal and emerging signals for ocular and pulmonary complications.
• Clinical Outcomes: Phase III data for semaglutide and tirzepatide demonstrate significant weight loss (14.9% to 22.5%) and cardiovascular risk reduction (20% MACE reduction), while other peptides like Thymosin Alpha-1 have shown negative results in specific indications such as sepsis.

What the Research Shows

Regulatory Status of Compounded Peptides

As of March 2026, the FDA has largely restricted the compounding of several popular peptides by placing them in Category 2 under 503A or 503B regulations. BPC-157 is listed in Category 2 due to immunogenicity concerns and a lack of safety data, rendering it ineligible for routine compounding. Similarly, TB-500 remains in Category 2 as the FDA cites immunogenicity risks and a total absence of human exposure data.

Several peptides previously nominated for compounding had their nominations withdrawn or were removed in September 2024. This includes CJC-1295, where the FDA cited safety issues such as increased heart rate, and AOD-9604, Ipamorelin, and Selank. While Selank and Semax are approved in Russia—Semax specifically for stroke—neither is FDA-approved in the United States. Thymosin Alpha-1 is approved in over 35 countries as Zadaxin but is not FDA-approved; it was removed from the Category 2 list pending advisory review in September 2024 but remains a substance of concern under interim policy.

Safety Signals from Post-Marketing Surveillance

FAERS data for semaglutide reveals a robust profile of gastrointestinal events. Nausea and vomiting show strong signal strength (elevated ROR) and are documented in Section 6 of the drug label. Delayed gastric emptying is also a strong signal (Section 5.10), noting its potential impact on oral medication absorption and its relevance as a pre-surgical concern.

Emerging and serious signals include:

• Intestinal Obstruction/Ileus: Added to the label post-marketing.
• Acute Pancreatitis: A moderate signal (elevated PRR) categorized as a boxed-adjacent warning.
• NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): An emerging signal with 96 cases reported through December 2024, prompting an EMA review in January 2025.
• Pulmonary Aspiration: Added to the Ozempic label in 2025, noted as a risk during general anesthesia due to delayed gastric emptying.
• Suicidal Ideation: Currently under evaluation; existing data does not support a higher risk compared to background levels, though monitoring is required.

Clinical Trial Evidence

High-grade evidence from Phase III trials confirms the efficacy of certain peptides for metabolic health. The STEP 1 trial (NCT03548935) showed a 14.9% weight loss with semaglutide, while the SELECT trial (NCT03574597) demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide (SURMOUNT-1) showed a 22.5% weight loss and was found superior to semaglutide in the SURMOUNT-5 head-to-head trial.

In contrast, Thymosin Alpha-1 failed to demonstrate a mortality reduction in its Phase III trial for sepsis (NCT02867267). Tesamorelin maintains its status for HIV-associated lipodystrophy based on an 18% reduction in visceral adipose tissue (VAT) from its pivotal Phase III trial.

Mechanism

Mechanistic data provided focuses on clinical outcomes and safety risks. For peptides like BPC-157 and GHK-Cu, the primary clinical concern cited is immunogenicity. Semaglutide and other GLP-1 RAs contribute to conditions such as pulmonary aspiration and various gastrointestinal issues through the mechanism of delayed gastric emptying. CJC-1295 is associated with an increased heart rate.

Limitations of the Evidence

A major limitation is the lack of human exposure data for substances like TB-500. For many peptides in Category 2, such as BPC-157, the FDA notes a significant lack of available safety data. While FAERS provides volume-based signal detection, current data on suicidal ideation for GLP-1 RAs remains inconclusive against background population rates. Additionally, some peptides like Selank and Semax lack FDA-scrutinized safety data despite being approved in other jurisdictions like Russia.

Clinical Takeaway

Physicians should be aware that the FDA has categorized the majority of non-approved compounding peptides (including BPC-157, TB-500, and CJC-1295) as Category 2 substances due to immunogenicity risks and safety concerns. While semaglutide and tirzepatide have robust Phase III evidence for weight loss and cardiovascular benefit, they are associated with significant gastrointestinal signals and emerging risks regarding pulmonary aspiration and optic neuropathy (NAION) that require clinical vigilance.

Sources

1. FDA Regulatory Status Records (0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b).
2. FAERS Safety Signals (502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa).
3. Clinical Trial Records (NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267).